Development & Marketing Strategy on Daiichi Sankyo's DS-1062, $6 billion collaboration deal
By: Mellalta Meets
As per the agreement, AstraZeneca will pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment for New Global Development and Commercialization for Daiichi Sankyo's DS-1062. This is the second collaboration happening between the two Pharma giants. Previously they collaborated to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019.
Daiichi Sankyo's DS-1062 Development Strategy
Daiichi Sankyo's DS-1062 is one of the three lead DXd ADCs in the oncology pipeline of Daiichi Sankyo. It is a TROP2-directed antibody drug conjugate (ADC), designed using Daiichi Sankyo's proprietary DXd ADC technology with the highest development stage of Phase II.
In ASCO 2020, in its first-in-human Phase I study, DS-1062 has shown efficacy and the antibody drug conjugate well tolerated up to 8 mg/kg, and a dose effect on antitumor activity was observed over 2.0-10.0 mg/kg in heavily pre-treated with prior progression on standard treatment. The study is still ongoing in patients with unresectable Non-Small Cell Lung cancer and Triple Negative Breast Cancer refractory to/relapsed from standard treatment with measurable disease.
Another study has been newly announced by Daiichi is a Phase II multicenter, randomized study of DS-1062a in advanced or metastatic non-small cell lung cancer with actionable genomic alterations and previously treated with kinase inhibitor therapy and platinum-based chemotherapy with or without prior immunotherapy. The study will begin from October 2020. This study is in collaboration with Gustave Roussy .
Dosage which will get checked for DS-1062a are 8.0 mg/kg and 6.0 mg/kg
DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks at 2 cycles
Secret Sauce by Daiichi: DS-1062 will also be checked in combination with PD-L1 therapy and several other undisclosed therapies [Click here]
Daiichi has also recently collaborated with Gustave Roussy and has signed a multi-year and multi-study research collaboration. The interest of the collaboration is to check the possible combinations of the two antibody-drug conjugates i.e DS-1062 (a TROP2 directed DXd ADC) and patritumab deruxtecan (a HER3 directed DXd ADC) for the treatment of patients with lung and breast cancer respectively.
Trials will be done at several sites in France [expected]
Additional research to be conducted under the collaboration includes several studies exploring multiple
therapeutic combinations for DS-1062